Efficacy of dried lime in common cold among Hajj pilgrims

Preventive efficacy of dried lime (Citrus aurantifulia) in common cold among Hajj pilgrims: A randomized, double-blind placebo-controlled clinical trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170704034897N2

Enrollment

126

Registered

2018-01-30

Start date

2014-09-10

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

common cold. Acute nasopharyngitis [common cold]

Interventions

Intervention 1: Intervention group: Patients in drug group received dried lime capsules, 500 mg in a single dose per day for four weak. Test drug consisting of Citrus aurantifulia and sugar. The dried

Treatment - Drugs

Placebo

Intervention group: Patients in drug group received dried lime capsules, 500 mg in a single dose per day for four weak. Test drug consisting of Citrus aurantifulia and sugar. The dried fruit of Citrus

Control group: In the placebo group, patients received placebo capsules with the same method.(a single dose per day for four weak) Placebo capsule, consisting of 550 milligrams of flour with identical

Eligibility

Sex/Gender

All

Age

35 Years to 80 Years

Inclusion criteria

Inclusion criteria: All men and women aged 35 to 80 years participating in the Hajj who agree with the aim of the study

Exclusion criteria

Exclusion criteria: participants who have asthma participants who have a chronic obstructive pulmonary disease participants who have uncontrolled heart diseases participants who have heart failure participants who have a hepatic and renal failure participants who have a history of previous chest surgery.

Design outcomes

Primary

Measure	Time frame
The severity of a cough. Timepoint: First , second, third and fourth week after intervention. Method of measurement: By self-administered questionnaire that ranged from 0-5 scores (without symptoms to severe symptoms).;The severity of rhinorrhea. Timepoint: First , second, third and fourth week after intervention. Method of measurement: By self-administered questionnaire that ranged from 0-5 scores (without symptoms to severe symptoms).;The severity of fever. Timepoint: First , second, third and fourth week after intervention. Method of measurement: By self-administered questionnaire that ranged from 0-5 scores (without symptoms to severe symptoms).;The severity of body pain. Timepoint: First , second, third and fourth week after intervention. Method of measurement: By self-administered questionnaire that ranged from 0-5 scores (without symptoms to severe symptoms).	—

Measure

Time frame

The severity of a cough. Timepoint: First , second, third and fourth week after intervention. Method of measurement: By self-administered questionnaire that ranged from 0-5 scores (without symptoms to severe symptoms).;The severity of rhinorrhea. Timepoint: First , second, third and fourth week after intervention. Method of measurement: By self-administered questionnaire that ranged from 0-5 scores (without symptoms to severe symptoms).;The severity of fever. Timepoint: First , second, third and fourth week after intervention. Method of measurement: By self-administered questionnaire that ranged from 0-5 scores (without symptoms to severe symptoms).;The severity of body pain. Timepoint: First , second, third and fourth week after intervention. Method of measurement: By self-administered questionnaire that ranged from 0-5 scores (without symptoms to severe symptoms).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Seyed Hossein Owji

Shiraz University of Medical Sciences

owji_h@sums.ac.ir+98 71 3212 2970

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026